Sirolimus conversion for renal preservation in liver transplantation: not so fast.
Jensen
Geoffrey S
GS
Wiseman
Alexander
A
Trotter
James F
JF
D000963:Antimetabolites / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced* / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D017582:Renal Replacement Therapy; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
D000963:Antimetabolites; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D020123:Sirolimus; D016559:Tacrolimus